Progyny, Inc. (NASDAQ:PGNY) Shares Acquired by AWM Investment Company Inc.

AWM Investment Company Inc. lifted its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 540.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 160,000 shares of the company's stock after acquiring an additional 135,000 shares during the period. AWM Investment Company Inc. owned 0.19% of Progyny worth $2,760,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Voya Investment Management LLC increased its stake in Progyny by 1.4% in the 4th quarter. Voya Investment Management LLC now owns 51,792 shares of the company's stock valued at $893,000 after buying an additional 701 shares during the period. Signaturefd LLC boosted its holdings in shares of Progyny by 1,355.0% in the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after acquiring an additional 1,355 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after acquiring an additional 1,526 shares during the period. KBC Group NV increased its stake in shares of Progyny by 84.6% during the fourth quarter. KBC Group NV now owns 4,669 shares of the company's stock worth $81,000 after acquiring an additional 2,140 shares during the period. Finally, F M Investments LLC raised its holdings in Progyny by 13.0% during the fourth quarter. F M Investments LLC now owns 20,420 shares of the company's stock worth $352,000 after purchasing an additional 2,342 shares in the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on PGNY. JPMorgan Chase & Co. raised their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective for the company in a research note on Monday, March 31st. Bank of America lifted their price objective on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. Finally, Canaccord Genuity Group lowered their target price on Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Progyny has an average rating of "Hold" and an average price target of $23.45.

Progyny Price Performance

NASDAQ PGNY traded down $0.37 on Monday, reaching $20.52. The company had a trading volume of 822,500 shares, compared to its average volume of 1,712,711. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $30.42. The firm has a 50-day moving average of $22.15 and a 200-day moving average of $19.98. The firm has a market capitalization of $1.76 billion, a PE ratio of 35.38, a P/E/G ratio of 2.39 and a beta of 1.37.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.28). The business had revenue of $324.04 million during the quarter, compared to analyst estimates of $307.86 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The company's revenue was up 16.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.17 EPS. As a group, sell-side analysts expect that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.